SEC Tracker
Get the app

Geron GERN

Geron reports Q3 2026 financial results

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. RYTELO net product revenue of $60.1 million in Q3 2026
  2. Reiterated 2026 RYTELO net product revenue at $220 million to $240 million
  3. Cash, cash equivalents, restricted cash, and marketable securities of $339 million as of Q3 2026
  4. Lowered 2026 total operating expenses to $220 million to $230 million

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Geron files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

  1. The filing includes a press release with details about its financial performance and business updates.
  2. The press release states that Geron achieved $60.1 million in RYTELO net product revenue in Q3 2026, a 5% increase from Q2 2026.
  3. The company reiterated its 2026 RYTELO net product revenue guidance at the mid-to-high end of the $220 million to $240 million range.
  4. It also lowered its 2026 total operating expenses range to $220 million to $230 million.
  5. The company ended Q3 2026 with $339 million in cash, cash equivalents, restricted cash, and marketable securities.
  6. A conference call and webcast were held on November 4, 2026.

6 of 6 claims matched the filing text.

From the filing

Item 2.02

Item 2.02

Results of Operations and Financial Condition

On November 4, 2026, Geron Corporation (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2026 and recent business highlights. A copy of the press release is attached as Exhibit 99.11.

The information contained in Item 2.02 and in the accompanying Exhibit 99.1 to this Current Report shall be deemed to be "furnished" and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and shall not be incorporated by reference into any filing made by the Company with the U.S. Securities and Exchange Commission under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

No.

Description

99.1

Press release titled "Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights," dated November 4, 2026

104

Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GERON CORPORATION

Date: November 4, 2026

By:

/s/ Timothy Williams

Name:

Timothy Williams

Title:

Executive Vice President,

Chief Legal Officer and Corporate Secretary

Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights

Achieved $60.1 million in RYTELO (imetelstat) net product revenue in Q3 2026, an increase of 5% compared to Q2 20262 Reiterated 2026 RYTELO net product revenue at the mid-to-high end of the $220 million to $240 million range3; lowered 2026 total operating expenses range to $220 million to $230 million4

Initiated gated commercial launch to expand RYTELO access to eligible LR-MDS patients in targeted

European markets, with availability expected in Germany by end of year

Ended Q3 2026 with cash, cash equivalents, restricted cash, and marketable securities of $339 million5 Company to host conference call and webcast today, November 4, 2026, at 8:00 a.m. ET6

FOSTER CITY, Calif., November 4, 2026 (GLOBE NEWSWIRE) – Geron Corporation (Nasdaq: GERN), a hematology-focused commercial stage biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today reported financial results for the third quarter of 2026 and recent business highlights.

"Another quarter of strong RYTELO demand growth reinforces our confidence in the LR-MDS commercial opportunity and our ability to reach more second-line patients. Increased demand g

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Intellia Therapeutics NTLA public float $869M, Jun 30, 2025
  2. Wave Life Sciences WVE public float $851M, Jun 30, 2025
  3. CorMedix CRMD public float $910M, Jun 30, 2025
  4. Niagen Bioscience NAGE public float $814M, Jun 30, 2025
  5. Nurix Therapeutics NRIX public float $808M, May 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.